Dr Bridget Draper
Senior Research Officer
Background
Bridget works as a Senior Research Officer in the Disease Elimination program, with a specific focus on viral hepatitis projects in low- and middle-income countries. She currently works on the TREAT-HEP Myanmar project and the HepC CUTTS project.
Bridget completed a Bachelor of Arts (International Studies) at RMIT and her honours in Health Sciences through Monash University at the Burnet Institute. Her honours project focussed on acceptability of HIV pre-exposure prophylaxis among men who have sex with men in Myanmar. In 2022, Bridget completed her PhD exploring how to provide hepatitis C testing and treatment in resource-constrained settings using implementation science and health service delivery research methods.
Her work involved evaluating hepatitis C treatment programs in specialist and primary care settings in Myanmar, including the CT2 Study and evaluation of the National Hepatitis Control Program.
Qualifications
- 2022: Doctor of Philosophy, Monash University, Australia
- 2015: Honours (Health Sciences), Monash University, Australia
- 2014: Bachelor of Arts (International Studies), RMIT, Australia
Burnet publications
View 29 morePatients’ experience of accessing hepatitis C treatment through the Myanmar national hepatitis C treatment program: a qualitative evaluation
BMC Health Services Research
Bridget Draper et al
The National Naloxone Reference Group: A collective voice on take‐home naloxone policy and practice in Australia
Drug and Alcohol Review
Paul Dietze et al
Cost‐effectiveness of a decentralized, community‐based “one‐stop‐shop” hepatitis C testing and treatment program in Yangon, Myanmar
JGH Open
Thin Mar Win et al
Current projects
TREAT-HEP: community-based viral hepatitis testing and treatment project in Yangon, Myanmar
This project delivers hepatitis C prevention, testing and treatment services and hepatitis B testing and vaccination services.
CUTTS HepC: Catalysing uptake of under-utilised tools & treatment simplification for HepC
This project will generate evidence on how to improve hepatitis C prevention and care for people who inject drugs in low-and middle-income countries.
Past projects
View 1 more
The elimination of hepatitis C as a global public health threat
This project addresses critical knowledge gaps in Australian and global efforts to eliminate hepatitis C as a public health threat by 2030.
Eliminate C (EC) Victoria partnership
A partnership aimed at increasing hepatitis C treatment uptake among people who inject drugs (PWID) using nurse-led models of care in community and prison settings.
Hepatitis C: Community Testing and Treatment (CT2)
This study examined the feasibility of a community-based testing and treatment program for hepatitis C.
News and features
View 5 more
Australia Awards Fellows join Burnet to improve outcomes for people with hepatitis C
New treatment pathways for hepatitis C
Newly published Burnet study demonstrates the feasibility and effectiveness of simplified treatment of hepatitis C in Myanmar.
Burnet is part of global effort to prevent hepatitis C
Burnet Institute and partners have received US$31 million from global health agency Unitaid for an international harm reduction program.